Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data

AIM: Immune checkpoint inhibitors (ICIs) are a cornerstone in cancer treatment but they can induce immune-related adverse events (irAEs). Furthermore, patients with pre-existing autoimmune and/or inflammatory disease (AID) have been excluded from clinical trials. The objective of this study is to ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo, Virginia, Fernández, Marta Andrés, Collazo-Lorduy, Ana, Franco, Fernando, Núñez, Beatriz, Provencio, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656306/
https://www.ncbi.nlm.nih.gov/pubmed/34899991
http://dx.doi.org/10.2217/lmt-2021-0003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656306/
https://www.ncbi.nlm.nih.gov/pubmed/34899991
http://dx.doi.org/10.2217/lmt-2021-0003

Ejemplares similares